secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-04-14T23:59:59+00:00
Accession:  0001753926-25-000623
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella Pharmaceuticals regains Nasdaq equity compliance after $5.9M placement
------------------------------------------------------------------------------

- Final closing of Series B convertible preferred stock offering on March 12, 2025; net proceeds ~$5.9M.
- Also issued warrants to purchase up to 72,000 Series B shares at $100/share on March 17, 2025; gross proceeds $9,000.
- Stockholders' equity was ~$1.9M as of Dec 31, 2024; after offerings, company believes it meets Nasdaq's Stockholders' Equity Requirement.
- Nasdaq continued listing is subject to compliance; company states it currently remains in compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/0001753926-25-000623-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000623/g084773_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000623

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer